JP7036725B2 - Ｋｖ３チャネルのヒダントインモジュレーター - Google Patents

Ｋｖ３チャネルのヒダントインモジュレーター Download PDF

Info

Publication number
JP7036725B2
JP7036725B2 JP2018531529A JP2018531529A JP7036725B2 JP 7036725 B2 JP7036725 B2 JP 7036725B2 JP 2018531529 A JP2018531529 A JP 2018531529A JP 2018531529 A JP2018531529 A JP 2018531529A JP 7036725 B2 JP7036725 B2 JP 7036725B2
Authority
JP
Japan
Prior art keywords
disorders
alkyl
halo
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018531529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502696A5 (enExample
JP2019502696A (ja
Inventor
アルバロ ジュセッペ
マラスコ アゴスティーノ
デコル アンネ
ハムプレクフト ディエテル
Original Assignee
アウトイフオンイ トヘラペウトイクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アウトイフオンイ トヘラペウトイクス リミテッド filed Critical アウトイフオンイ トヘラペウトイクス リミテッド
Publication of JP2019502696A publication Critical patent/JP2019502696A/ja
Publication of JP2019502696A5 publication Critical patent/JP2019502696A5/ja
Application granted granted Critical
Publication of JP7036725B2 publication Critical patent/JP7036725B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018531529A 2015-12-16 2016-12-16 Ｋｖ３チャネルのヒダントインモジュレーター Expired - Fee Related JP7036725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1522179.9 2015-12-16
GBGB1522179.9A GB201522179D0 (en) 2015-12-16 2015-12-16 Novel compounds
PCT/GB2016/053958 WO2017103604A1 (en) 2015-12-16 2016-12-16 Hydantoin modulators of kv3 channels

Publications (3)

Publication Number Publication Date
JP2019502696A JP2019502696A (ja) 2019-01-31
JP2019502696A5 JP2019502696A5 (enExample) 2020-02-06
JP7036725B2 true JP7036725B2 (ja) 2022-03-15

Family

ID=55274838

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531529A Expired - Fee Related JP7036725B2 (ja) 2015-12-16 2016-12-16 Ｋｖ３チャネルのヒダントインモジュレーター

Country Status (7)

Country Link
US (1) US20200377485A1 (enExample)
EP (1) EP3390394B1 (enExample)
JP (1) JP7036725B2 (enExample)
CN (1) CN108430995A (enExample)
BR (1) BR112018012177A2 (enExample)
GB (1) GB201522179D0 (enExample)
WO (1) WO2017103604A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
HRP20241318T1 (hr) 2018-10-16 2024-12-20 Autifony Therapeutics Limited Novi spojevi
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
TW202031645A (zh) 2018-10-30 2020-09-01 丹麥商Ｈ 朗德貝克公司 作為Kv3鉀通道激活劑之芳基磺醯基吡咯甲醯胺衍生物
US20220220095A1 (en) 2019-04-26 2022-07-14 H. Lundbeck A/S N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
WO2020216919A1 (en) 2019-04-26 2020-10-29 H. Lundbeck A/S ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kν3 POTASSIUM CHANNEL ACTIVATORS
PH12022551955A1 (en) * 2020-02-06 2023-10-23 Autifony Therapeutics Ltd Novel compound
EP3901152A1 (en) * 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
IL310160A (en) 2021-08-10 2024-03-01 Autifony Therapeutics Ltd potassium channel modulators
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080100A1 (en) 2003-10-09 2005-04-14 Pfizer Inc Pyridylamino compounds and methods of use thereof
JP2005538155A (ja) 2002-09-05 2005-12-15 メディヴィル・アクチボラグ 非ヌクレオシド逆転写酵素インヒビター
JP2009533417A (ja) 2006-04-14 2009-09-17 ミュタビリス エス アー 新規ヒドロキシフェニル誘導体およびその生物学的適用
JP2013525433A (ja) 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
JP2014521625A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド 二環式ピリミドン化合物
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299383A (ja) * 1985-10-28 1987-05-08 Tokuyama Soda Co Ltd エ−テル化合物の製造方法
US9346790B2 (en) * 2010-12-06 2016-05-24 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
US20120316182A1 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6226967B2 (ja) * 2012-06-06 2017-11-08 ヴァンダービルト ケミカルズ、エルエルシー 燃費効率がよい潤滑油
CA2922567A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538155A (ja) 2002-09-05 2005-12-15 メディヴィル・アクチボラグ 非ヌクレオシド逆転写酵素インヒビター
US20050080100A1 (en) 2003-10-09 2005-04-14 Pfizer Inc Pyridylamino compounds and methods of use thereof
JP2009533417A (ja) 2006-04-14 2009-09-17 ミュタビリス エス アー 新規ヒドロキシフェニル誘導体およびその生物学的適用
JP2013525433A (ja) 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
JP2014521625A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド 二環式ピリミドン化合物
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Database REGISTRY，2008年05月，RN 1019484-48-0, 1019583-07-3，Retrieved from STN international [online] ;retrieved on 1 December 2020
Database REGISTRY，2013年，RN 1487198-59-3, 1099047-09-2, 1094719-31-9, 1019634-20-8, 1019633-19-2, 1019584-02-1, 1019558-63-4, 1019509-31-9, 1019509-28-4，Retrieved from STN international [online] ;retrieved on 1 April 2021

Also Published As

Publication number Publication date
BR112018012177A2 (pt) 2018-11-27
US20200377485A1 (en) 2020-12-03
WO2017103604A1 (en) 2017-06-22
GB201522179D0 (en) 2016-01-27
CN108430995A (zh) 2018-08-21
EP3390394A1 (en) 2018-10-24
EP3390394B1 (en) 2022-05-25
JP2019502696A (ja) 2019-01-31

Similar Documents

Publication Publication Date Title
JP7036725B2 (ja) Ｋｖ３チャネルのヒダントインモジュレーター
CN103596943B (zh) 用作kv3抑制剂的乙内酰脲衍生物
CN103974944B (zh) 用作kv3抑制剂的乙内酰脲衍生物
CN104334547A (zh) 作为kv3抑制剂的三唑类
JP7465868B2 (ja) 新規化合物
RS51066B (sr) Supstituisani derivati morfolina i tiomorfolina
WO2018109484A1 (en) Hydantoin modulators of kv3 channels
JP5744203B2 (ja) オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
JP7522203B2 (ja) Ｋｖ３モジュレーター
RU2830279C2 (ru) Новые соединения
US12358901B2 (en) KV3 modulators
AU2020427632B2 (en) Kv3 modulators
HK40081003B (zh) Kv3调节剂
KR20240133645A (ko) 옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
HK40081003A (en) Kv3 modulators
EA049235B1 (ru) Модуляторы kv3
HK40059039A (en) Novel compounds
HK40059039B (en) Novel compounds
BR112014013400B1 (pt) Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220303

R150 Certificate of patent or registration of utility model

Ref document number: 7036725

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees